Hikma Starts Seeing Benefits Of Stepping In On US Shortages
Helping to alleviate shortages of critical US injectables, including controlled substances, has strengthened Hikma’s relationships with its hospital customers in the US, including with Civica Rx, CEO Siggi Olafsson told Generics Bulletin.
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Hikma has set out updated full-year forecasts in a trading update that indicates its 2019 generics sales will hit the “top end” of its $690m-$720m expectations.